

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Touyun Biotech Group Limited
透雲生物科技集團有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 1332)

CLARIFICATION ANNOUNCEMENT

UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Touyun Biotech Group Limited (the “**Company**“, together with its subsidiaries, the “**Group**”) at the request of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) pursuant to Rule 13.10(2) of the Rules Governing the Listing of Securities on the Stock Exchange.

The Board has noted the increase in the share price and trading volume of the shares (the “**Shares**”) of the Company on 30, 31 October 2025 and 3 November 2025. Having made such enquiries with respect to the Company as are reasonable in the circumstances, save as previously disclosed and disclosed below, the Board confirms that it is not aware of any reasons for such price and trading volume movements or any information that needs to be disclosed to avoid a false market in the Company’s securities, or any inside information that needs to be disclosed under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). The Board also confirms that the Group’s business operation remains normal, and there is no material change to the business operation and financial position of the Group as at the date of this announcement.

The Board is pleased to provide a business update to the shareholders and potential investors of the Company that Shanxi Touyun Biotechnology Co., Ltd* (“**Shanxi Touyun**”), a wholly owned subsidiary of the Company has signed a Strategic Cooperation Agreement (the “**Strategic Cooperation Agreement**”) with Shenzhen Louyujian Supply Chain Technology Co., Ltd.*, Henan Guozitou Marketing Management Co., Ltd.*, and Beijing Hewanjia Biotechnology Co., Ltd.* (collectively the “**Sales Consortium**”) on 23 October 2025. According to the Strategic Cooperation Agreement, during the period from 2026 to 2028, the Sales Consortium shall purchase *Chlamydomonas reinhardtii* and related products from Shanxi Touyun with a total value not less than RMB1 billion. The specific commercial terms, including but not limited to selling price, quantity and delivery methods, are subject

to further negotiations between the contracting parties, and no formal purchase agreement has been signed yet. This Strategic Cooperation Agreement is part of the Group's normal business operations to explore market opportunities for its *Chlamydomonas reinhardtii* product series.

As the transactions contemplated under the Strategic Cooperation Agreement may or may not be materialized, shareholders and potential investors of the Company are advised to exercise caution in dealing with securities of the Company.

** for translation purpose only.*

By order of the Board
Touyun Biotech Group Limited
Wang Liang
Chairman

Hong Kong, 3 November 2025

As at the date of this announcement, the Board comprises the following directors:

Executive Directors

Mr. Wang Liang (*Chairman*)
Mr. Du Dong

Non-executive Directors

Mr. Chen Hui
Ms. Tian Yuze
Mr. Zhang Lele

Independent Non-executive Directors

Mr. Cheung Wing Ping
Mr. Ha Kee Choy Eugene
Mr. To Shing Chuen